The North America advanced medical stopcock market is expected to grow from US$ 335. 94 million in 2021 to US$ 430. 56 million in 2028; it is estimated to grow at a CAGR of 3. 7% from 2022 to 2028. The market growth is mainly attributed to factors such as the growing incidence of chronic diseases and a surge in the number of surgical procedures.
New York, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Advanced Medical Stopcock Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Type and End User" - https://www.reportlinker.com/p06373255/?utm_source=GNW However, the safety concerns regarding stopcocks are hampering the market growth. The North America advanced medical stopcock market is segmented into the US, Canada, and Mexico.The US is the largest market for advanced medical stopcocks, followed by Canada and Mexico. The increasing geriatric population, rising prevalence of chronic diseases such as cancer, favorable reimbursement for intravenous therapy in the homecare setting in the US and Canada are likely to drive the North America advanced medical stopcock market over the forecast period. In addition, the increasing number of surgeries and growing medical tourism in Mexico are likely to foster the growth of the market from 2022 to 2028. Surge in Number of Surgical Procedures Medical stopcocks are used with infusion pumps to administer medications through the catheter to a specific part of the body during or after surgical procedures.Infusion therapy is used when other methods are less effective or when the patient needs medication for the long term. Stopcocks are used to provide medicines in a fluid form when the patient is under observation after surgeries.The number of surgical procedures such as caesarean sections is growing across North America. According to the statistics revealed by the CDC, in 2020, approximately 1,148,692 million C-sections were performed in the US.Further, in Canada, ~105,000 C-sections are performed every year, making it the most common hospital-based surgery in the country. In addition, caesarean delivery rates in Mexico are among the highest in the world. Moreover, as per the Centers for Disease Control and Prevention (CDC), every year, ~805,000 people in the US suffer from a heart attack. It has also been estimated that 1 patient in every 34 seconds dies due to cardiovascular disease (CVD) in the country, and ~20.1 million adults have coronary artery disease (CAD). As a result, the number of cardiovascular surgeries has increased across the region. Thus, the surge in CVD patient population is increasing the number of angiography or angioplasty procedures. These procedures require high-pressure stopcocks; hence, the demand for advanced medical stopcocks is also increasing across the region. Thus, the surge in the number of surgical procedures is driving the North America advanced medical stopcock market. Based on type, the North America advanced medical stopcock market is segmented into low-pressure stopcocks, medium-pressure stopcocks, and high-pressure stopcocks.The low-pressure stopcocks segment held the largest share of the market in 2021, and it is expected to register the highest CAGR during the forecast period. The low-pressure stopcocks are designed to control the flow of a liquid or gas by using an on/off diverter cock.The pressure of the low-pressure stopcock is 200 psi. These stopcocks offer various advantages such as accuracy, convenience, and flow control per the requirement.The low-pressure stopcock is available in one-way, two-way, and three-way configurations. These enable inserting different fluids in different ways. The low-pressure stopcocks are used in medical and laboratory practices and enable the treatment of patients who require an accurate flow of medicines. Based on end user, the North America advanced medical stopcock market is segmented into hospitals & clinics, homecare, and ambulatory surgery centers. The hospitals & clinics segment held the largest share of the market in 2021. The World Health Organization (WHO), National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC), American Society for Clinical Pathology, American Diabetes Association, and Globocan are among the major primary and secondary sources referred to while preparing the report on the North America advanced medical stopcock market. Read the full report: https://www.reportlinker.com/p06373255/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________
The stock market seems bound and determined to leave investors with bad memories of 2022, with major market benchmarks once again failing to deliver even a tiny bounce as the end of the year approaches. Losses for the Dow Jones Industrial Average (DJINDICES: ^DJI), Nasdaq Composite (NASDAQINDEX: ^IXIC), and S&P 500 (SNPINDEX: ^GSPC) all topped 1% as investors continue worrying about whether the macroeconomic picture in 2023 will remain just as cloudy as it is today. For investors looking for more immediate recognition of their achievements, though, TG Therapeutics (NASDAQ: TGTX) saw its stock move higher after getting good news from the U.S. Food and Drug Administration.
There's a short answer to whether CRISPR Therapeutics (NASDAQ: CRSP) could help you become a millionaire: Yes. Here are five reasons why the company, which just went public in 2016, could make you a millionaire. CRISPR and Vertex Pharmaceuticals say they expect to complete their biologics license application early next year for exa-cel, to treat blood disorders beta-thalassemia and severe sickle cell disease.
It’s a big day for shareholders of tiny Kala Pharmaceuticals. The biotech company, which aims to treat rare diseases of the eye, said Tuesday that the Food and Drug Administration has accepted the company’s investigational new drug application for its lead drug candidate, known as KPI-012. That means the company can start a fresh clinical trial early next year for the drug candidate, which aims to treat a disease called persistent corneal epithelial defect. Kala shares more than tripled in Wedne
Investors are closely watching two Eli Lilly battles that will unfold in 2023 as LLY stock continues a fevered streak, tacking on new highs.
The FDA approves Acer Therapeutics' (ACER) Olpruva (sodium phenylbutyrate) to treat certain patients with urea cycle disorders. Share price falls 33.3% following the announcement.
Rep. Jamie Raskin, a prominent member of the Jan. 6 committee and a former Trump impeachment manager, announced Wednesday that he's been diagnosed with cancer.
Denise Austin skyrocketed to fame in the ‘80s and ‘90s with the “8-minute abs” workout. She has sold more than 24 million exercise videos and DVDs over the years.
Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) at the request of IIROC the Company would like to provide clarification on the disclosure regarding the diagnostic and therapeutic technologies of the Company and its subsidiaries Sepset Biosciences Inc. ("Sepset") and ABT Innovations Inc. ("ABT") that was included in a news release dated December 23, 2022.
Biotech firm developing potential treatment for rare eye disease called "persistent corneal epithelial defect."
CureVac N.V. (NASDAQ:CVAC) Q3 2022 Earnings Call Transcript November 16, 2022 CureVac N.V. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.27. Operator: Greetings, and welcome to CureVac Third Quarter and First Nine Months 2022 Financial Results and Business Update. At this time, all participants are in a listen-only mode. A brief question-and-answer session […]
Kaiser Health News and CBS News investigation found just how frustrating a hospital clerical error can be to fix
In this piece, we will take a look at the ten most advanced countries in dentistry. For more companies, head on over to 5 Most Advanced Countries in Dentistry. Whether a dentist is a doctor or not is still up for debate, but what is for sure is that dentists play an important role in […]
As Covid's travel nursing boom began to wane, nurses attracted by talk of high wages found themselves far from home with their pay cut at renewal time.
The United States will impose mandatory COVID-19 tests on travelers from China, U.S. health officials said on Wednesday, joining India, Italy, Japan and Taiwan in taking new measures after Beijing's decision to lift stringent zero-COVID policies. The officials told reporters that beginning on Jan. 5, all air passengers 2 years old and older will require a negative result from a test no more than two days before departure from China, Hong Kong or Macao. They attributed the change in policy to the lack of information on variants of the SARS-CoV-2 virus and concerns that the increased number of COVID cases in China could result in the development of new variants of the virus.
TG Therapeutics Inc said on Wednesday that the U.S. health regulator had approved its monoclonal antibody for treating patients with relapsing forms of multiple sclerosis, sending its shares up 47% in afternoon trade. The approval by the U.S. Food and Drug Administration (FDA) widens the number of such drugs available for treating the disorder to three and may help soften the blow to the company's finances from the withdrawal of its lymphatic cancer drug earlier this year. Jefferies analyst Chris Howerton said ahead of the approval that he was expecting the drug to be priced in the range of $30,000 per patient per year.
Preliminary data from a randomized clinical trial may point to a potential way to prevent long covid. The trial found that covid-19 patients who took metformin, a commonly prescribed diabetes drug, were noticeably less likely to be diagnosed with long covid up to 10 months later than people in the control group. More research will be needed to confirm the implications of this study, however.
The answer, for now, may not matter, experts say. Here's why.
Healthy aging isn't just about good genes. People who have turned 100 share tips on longevity and how to live a longer life with exercise, diet, optimism.
One can invest in Sanofi (SNY) due to the strong performance of Dupixent, above-market sales growth of the Consumer unit, consistent pipeline innovation and regular accretive collaboration deals.
Raskin, a Democrat from Maryland, said he will begin chemo-immunotherapy treatments on an outpatient basis.